Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases.  The Company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease.  Madrigal’s lead drug candidate is 3196, a Phase 1 orally administered liver-directed thyroid hormone receptor-ß agonist (THR-ß) for the treatment of dyslipidemia/hypercholesterolemia, including high LDL cholesterol, high triglycerides, and elevated Lipoprotein (a) (Lp(a)).  3196 is designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with THR activation outside the liver.  Its mechanisms of action are distinct from and complementary to statins.   Madrigal is also developing a Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor for diabetes, a target with potential additional application in weight control and dyslipidemia.